Zyprexa Medicaid Cost Highlight Of OIG’s Mental Health Rx Spending Report

The HHS Office of Inspector General's report on Medicaid spending for mental health drugs singles out Lilly's Zyprexa (olanzapine) as a particularly costly product for the program